MCID: OVR105
MIFTS: 38

Ovarian Serous Carcinoma

Categories: Endocrine diseases, Reproductive diseases, Cancer diseases

Aliases & Classifications for Ovarian Serous Carcinoma

MalaCards integrated aliases for Ovarian Serous Carcinoma:

Name: Ovarian Serous Carcinoma 12 15
Ovarian Serous Adenocarcinoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050933

Summaries for Ovarian Serous Carcinoma

Disease Ontology : 12 An ovarian carcinoma that has material basis in the lining of the ovary and produces a serum-like fluid.

MalaCards based summary : Ovarian Serous Carcinoma, also known as ovarian serous adenocarcinoma, is related to primary peritoneal carcinoma and dermatomyositis. An important gene associated with Ovarian Serous Carcinoma is MIR21 (MicroRNA 21
Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Bevacizumab and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and bone.

Related Diseases for Ovarian Serous Carcinoma

Diseases related to Ovarian Serous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 primary peritoneal carcinoma 11.5
2 dermatomyositis 10.4 MIR21 MIR214
3 peritonitis 10.2
4 ovarian epithelial cancer 10.2 MIR100 MIR125A
5 facioscapulohumeral muscular dystrophy 1 10.1 MIR21 MIR214 MIR29A MIRLET7B
6 peritoneal mesothelioma 10.0
7 ulcerative colitis 10.0 MIR21 MIR23A MIR23B MIR29A
8 muscular dystrophy, limb-girdle, type 2a 10.0 MIR214 MIRLET7B
9 pancreatitis, hereditary 9.9 MIR10B MIR125A MIR99A
10 glioblastoma 9.8 MIR10B MIR21 MIR23A MIR23B
11 parametritis 9.8
12 pancreatic ductal carcinoma 9.8
13 pancreatitis 9.8
14 uterine corpus serous adenocarcinoma 9.8
15 endometrioid ovary carcinoma 9.8
16 mediastinitis 9.8
17 hypoxia 9.8
18 malignant peritoneal mesothelioma 9.8
19 endotheliitis 9.8
20 thyroid cancer, nonmedullary, 1 9.7 MIR200A MIR21 MIR29A MIRLET7B
21 squamous cell carcinoma, head and neck 9.7 MIR141 MIR200A MIR21 MIR214
22 kidney cancer 9.7 MIR141 MIR21 MIR27A MIR29A
23 nonalcoholic fatty liver disease 9.6 MIR10B MIR27A
24 psoriasis 9.5 MIR100 MIR141 MIR200A MIR21
25 esophagus adenocarcinoma 9.4 MIR143 MIR145 MIR21
26 autism spectrum disorder 9.4 MIR21 MIR23A MIR27A MIR93
27 leukemia, acute lymphoblastic 9.2 MIR125A MIR21 MIR23A MIR23B MIR27A MIRLET7B
28 leukemia, acute myeloid 9.1 MIR125A MIR21 MIR23A MIR23B MIR27A MIRLET7B
29 cervical cancer 9.0 MIR143 MIR21 MIR214 MIR23B MIRLET7B
30 neuroblastoma 9.0 MIR125A MIR23B MIR29A MIR93 MIR99A MIRLET7B
31 diffuse large b-cell lymphoma 8.9 MIR143 MIR145 MIR21 MIR99A
32 vascular disease 8.8 MIR125A MIR143 MIR145 MIR21 MIR214
33 pancreatic ductal adenocarcinoma 8.7 MIR141 MIR143 MIR145 MIR21 MIR93
34 melanoma 8.6 MIR100 MIR141 MIR200A MIR23B MIR27A MIRLET7B
35 leukemia, chronic lymphocytic 8.0 MIR10B MIR141 MIR143 MIR145 MIR21 MIR23B
36 ovarian cancer 7.8 MIR100 MIR10B MIR125A MIR141 MIR200A MIR21
37 endometriosis 7.7 MIR100 MIR125A MIR141 MIR143 MIR145 MIR200A
38 gastric cancer 7.6 MIR141 MIR143 MIR145 MIR21 MIR214 MIR27A
39 bladder cancer 7.6 MIR100 MIR10B MIR143 MIR145 MIR21 MIR23A
40 pancreatic cancer 7.5 MIR100 MIR10B MIR125A MIR143 MIR21 MIR214
41 oral squamous cell carcinoma 7.4 MIR100 MIR143 MIR145 MIR21 MIR23A MIR23B
42 breast cancer 6.8 MIR10B MIR125A MIR141 MIR143 MIR145 MIR200A
43 lung cancer 5.9 MIR100 MIR125A MIR141 MIR143 MIR145 MIR200A
44 colorectal cancer 5.8 MIR100 MIR10B MIR125A MIR141 MIR143 MIR145
45 prostate cancer 5.2 MIR100 MIR10B MIR125A MIR141 MIR143 MIR145
46 hepatocellular carcinoma 4.9 MIR125A MIR141 MIR143 MIR145 MIR200A MIR21

Graphical network of the top 20 diseases related to Ovarian Serous Carcinoma:



Diseases related to Ovarian Serous Carcinoma

Symptoms & Phenotypes for Ovarian Serous Carcinoma

Drugs & Therapeutics for Ovarian Serous Carcinoma

Drugs for Ovarian Serous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
2
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3 23214-92-8 31703
5
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
6
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
7
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
8
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
9
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3 119413-54-6, 123948-87-8 60700
10
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
11
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
12
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
13
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
14
Doxil Approved June 1999 Phase 2, Phase 3,Phase 3 31703
15
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
16
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
17 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
18 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
19 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
20 Antibodies Phase 3,Phase 2,Phase 1
21 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
22 Antimitotic Agents Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
25 Immunoglobulin G Phase 3,Phase 2,Phase 1
26 Immunoglobulins Phase 3,Phase 2,Phase 1
27 Mitogens Phase 3,Phase 2,Phase 1
28 Carotenoids Phase 3
29 Micronutrients Phase 3
30 Trace Elements Phase 3
31 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3
32 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3
33 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3
34 Anti-Infective Agents Phase 3,Phase 1,Phase 2
35 Antimetabolites Phase 3,Phase 1,Phase 2
36 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
37 Antiviral Agents Phase 3,Phase 1,Phase 2
38 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
39 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
40 Anticoagulants Phase 2, Phase 3
41 Antineoplastic Agents, Hormonal Phase 2, Phase 3
42 Aromatase Inhibitors Phase 2, Phase 3
43 Bone Density Conservation Agents Phase 2, Phase 3
44 Calcium, Dietary Phase 2, Phase 3
45 Chelating Agents Phase 2, Phase 3
46 Estrogen Antagonists Phase 2, Phase 3
47 Estrogen Receptor Modulators Phase 2, Phase 3
48 Estrogens Phase 2, Phase 3
49 Hormone Antagonists Phase 2, Phase 3
50 Hormones Phase 2, Phase 3

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
3 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
4 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
5 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
6 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
7 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
8 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
9 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Recruiting NCT02953457 Phase 1, Phase 2 Olaparib
10 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02853318 Phase 2 Cyclophosphamide
11 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
12 Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02627443 Phase 1, Phase 2 ATR Kinase Inhibitor M6620;Carboplatin;Gemcitabine Hydrochloride
13 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
14 Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Active, not recruiting NCT00551070 Phase 2 Selumetinib Sulfate
15 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT01116648 Phase 1, Phase 2 Cediranib Maleate;Olaparib
16 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
17 Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02345265 Phase 2 Cediranib Maleate;Olaparib
18 Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not yet recruiting NCT02756130 Phase 1, Phase 2 Birinapant;Carboplatin
19 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
20 To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers Recruiting NCT02179970 Phase 1 Plerixafor
21 Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Recruiting NCT02898207 Phase 1 Olaparib;Onalespib
22 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
23 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
24 Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn NCT02627430 Phase 1 Hsp90 Inhibitor AT13387;Talazoparib
25 Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System Completed NCT00837993
26 Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity Completed NCT02016833

Search NIH Clinical Center for Ovarian Serous Carcinoma

Genetic Tests for Ovarian Serous Carcinoma

Anatomical Context for Ovarian Serous Carcinoma

MalaCards organs/tissues related to Ovarian Serous Carcinoma:

41
Ovary, Endothelial, Bone, Lung, Testis

Publications for Ovarian Serous Carcinoma

Articles related to Ovarian Serous Carcinoma:

(show top 50) (show all 106)
# Title Authors Year
1
TBX2 expression is associated with platinum-sensitivity of ovarian serous carcinoma. ( 29435041 )
2018
2
Expression of UCP2 is associated with sensitivity to platinum-based chemotherapy for ovarian serous carcinoma. ( 29928365 )
2018
3
Decreased Eph receptora89A1 expression is related to grade in ovarian serous carcinoma. ( 29393455 )
2018
4
Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer. ( 29668586 )
2018
5
Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. ( 28959512 )
2017
6
ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy. ( 28178720 )
2017
7
EphB3 protein is associated with histological grade and FIGO stage in ovarian serous carcinomas. ( 28120491 )
2017
8
PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. ( 28877056 )
2017
9
High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. ( 29262533 )
2017
10
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. ( 28196634 )
2017
11
Aldehyde dehydrogenase 1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma. ( 28851663 )
2017
12
A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma. ( 27836204 )
2017
13
Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight. ( 28599499 )
2017
14
miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma. ( 29079174 )
2017
15
Metastatic Ovarian Serous Carcinoma of the Breast. ( 27943469 )
2016
16
Gene Set-Based Functionome Analysis of Pathogenesis in Epithelial Ovarian Serous Carcinoma and the Molecular Features in Different FIGO Stages. ( 27275818 )
2016
17
B7-H4 Expression in Ovarian Serous Carcinoma: A Study of 306 Cases. ( 27349304 )
2016
18
Immunostaining Study on the Expression of NF-I_B, ER, and PR in Ovarian Serous Carcinoma. ( 27171541 )
2016
19
EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma. ( 27887627 )
2016
20
Letter to the Editor on "Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?" Int J Gynecol Cancer 2015;25: 1201-1207. ( 26807559 )
2016
21
Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma. ( 27802199 )
2016
22
PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. ( 26504072 )
2015
23
Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival. ( 26468391 )
2015
24
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. ( 25455994 )
2015
25
Expression pattern of RAGE and IGF-1 in the human fetal ovary and ovarian serous carcinoma. ( 25724694 )
2015
26
Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma. ( 26250968 )
2015
27
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma. ( 26232338 )
2015
28
Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma? ( 26035124 )
2015
29
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma. ( 25889687 )
2015
30
Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. ( 24888238 )
2014
31
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. ( 24814803 )
2014
32
Expression of p-Akt in ovarian serous carcinoma and its association with proliferation and apoptosis. ( 24348821 )
2014
33
Overexpression of I^-catenin and cyclinD1 predicts a poor prognosis in ovarian serous carcinomas. ( 24427347 )
2014
34
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. ( 24756216 )
2014
35
Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis. ( 24262874 )
2014
36
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival. ( 24926085 )
2014
37
Migfilin, I+-parvin and I^-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases. ( 23099104 )
2013
38
P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas. ( 23388101 )
2013
39
Ovarian serous carcinoma associated with a distinct "corded and hyalinized" pattern. ( 23368871 )
2013
40
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma. ( 23656974 )
2013
41
miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1. ( 23722670 )
2013
42
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. ( 24060004 )
2013
43
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. ( 23438671 )
2013
44
FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. ( 23354471 )
2013
45
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. ( 24011953 )
2013
46
Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. ( 23850493 )
2013
47
MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. ( 23836287 )
2013
48
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. ( 23114921 )
2013
49
The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma. ( 23762804 )
2013
50
AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma. ( 23242172 )
2013

Variations for Ovarian Serous Carcinoma

Copy number variations for Ovarian Serous Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 109396 17 25800000 31800000 Deletion NF1 Ovarian serous carcinoma

Expression for Ovarian Serous Carcinoma

Search GEO for disease gene expression data for Ovarian Serous Carcinoma.

Pathways for Ovarian Serous Carcinoma

Pathways related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 MIR100 MIR10B MIR125A MIR141 MIR143 MIR145
2 11.13 MIR100 MIR145 MIR23A MIR23B MIR27A MIR93
3 10.89 MIR141 MIR200A
4 10.6 MIR29A MIRLET7B

GO Terms for Ovarian Serous Carcinoma

Cellular components related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.44 MIR100 MIR10B MIR125A MIR141 MIR143 MIR21

Biological processes related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.88 MIR125A MIR21 MIR23B MIR29A
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.81 MIR21 MIR27A MIRLET7B
3 negative regulation of gene expression GO:0010629 9.78 MIR125A MIR21 MIR23B MIR29A
4 positive regulation of protein kinase B signaling GO:0051897 9.77 MIR143 MIR21 MIR29A
5 negative regulation of cell migration GO:0030336 9.71 MIR21 MIR214 MIR29A
6 positive regulation of angiogenesis GO:0045766 9.67 MIR143 MIR21 MIR29A MIRLET7B
7 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.63 MIR21 MIR29A
8 positive regulation of endothelial cell migration GO:0010595 9.63 MIR21 MIR29A
9 positive regulation of blood vessel endothelial cell migration GO:0043536 9.62 MIR143 MIR200A
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.62 MIR21 MIR214
11 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.61 MIR145 MIR21
12 activation of protein kinase B activity GO:0032148 9.61 MIR143 MIR21
13 negative regulation of smooth muscle cell proliferation GO:0048662 9.6 MIR143 MIR145
14 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.58 MIR143 MIR21
15 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.57 MIR10B MIRLET7B
16 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.56 MIR21 MIR214
17 regulation of smooth muscle contraction GO:0006940 9.55 MIR143 MIR145
18 cell growth involved in cardiac muscle cell development GO:0061049 9.52 MIR23A MIR23B
19 negative regulation of cardiac muscle hypertrophy GO:0010614 9.51 MIR145 MIR21
20 angiotensin-activated signaling pathway GO:0038166 9.49 MIR143 MIR145
21 gene silencing by miRNA GO:0035195 9.47 MIR10B MIR125A MIR141 MIR143 MIR145 MIR200A
22 aorta smooth muscle tissue morphogenesis GO:0060414 9.46 MIR143 MIR145
23 miRNA mediated inhibition of translation GO:0035278 9.46 MIR145 MIR21 MIR27A MIR29A
24 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.43 MIR21 MIRLET7B
25 positive regulation of vascular endothelial cell proliferation GO:1905564 9.43 MIR21 MIR27A MIR29A
26 negative regulation of angiogenesis GO:0016525 9.43 MIR125A MIR143 MIR145 MIR21 MIR214 MIR29A
27 regulation of phenotypic switching GO:1900239 9.4 MIR143 MIR145
28 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.32 MIR143 MIR145

Molecular functions related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIR10B MIR125A MIR141 MIR143 MIR145 MIR200A
2 RNA polymerase II core binding GO:0000993 8.96 MIR125A MIR145

Sources for Ovarian Serous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....